Participating in research can be a rewarding experience, and is essential to improve the quality of life of people with lupus.
News & Stories
Lupus organizations announce groundbreaking collaborative initiative to inform lupus drug development.
This month, Dr. Emily von Scheven answers your questions about steroid treatments for children and teens with lupus.
According to lead author, Dr. Ian Bruce, at the University of Manchester, UK, the results are encouraging
A new study points to specific changes companies can make in clinical trials so that, in the future, clearer data can lead us closer to a cure.
Ask The Experts: Sarah Stothers, National Nurse Health Educator provides information about self-advocacy in lupus.
Anifrolumab significantly reduced disease activity as measured by several SLE composite endpoints and improved symptoms of lupus.
Fans may be surprised she mentions that she has received chemotherapy for her lupus.
A new analysis of data from a phase II clinical study of Edratide support the need for additional longer term studies in lupus.
Off-label drugs for the treatment of lupus symptoms represents the standard of care for people with lupus, but current regulations make it difficult for doctors and manufacturers to communicate. Read Sandra C. Raymond's remarks now.
Further studies may lead to interventions that improve the health outcomes of people with lupus.
Lupus is an autoimmune disease in which people generate antibodies against their own organs. But when antibodies to phospholipid-binding proteins are involved, a variety of complications can occur.
A new research study by Foundation grantee Dr. Laurence Morel identifies a lupus related gene that affects adult mesenchymal stem cells. Read more.
Part of a new analysis from the ongoing Hopkins Lupus Cohort provides new knowledge that may help physicians make decisions about gradually reducing corticosteroid doses in people with lupus.
When the Lupus Foundation of America became aware of a hydroxychloroquine (Plaquenil®) shortage, we set out to discover the root of problem. While we still have limited information, we want to alert our constituents to the facts of the situation.
Lupus experts predict next years of progress
The Lupus Foundation of America Corporate Advisory Council provides industry perspective helping identify and address barriers to lupus drug development.
LFA-REAL is a two part system, based on a series of simple questions and observations, to determine a treatment’s impact on the patient’s health and daily life.
Sandra C. Raymond, President & CEO of the Lupus Foundation of America, issued the following statement in response to Eli Lilly and Company’s announcement of the results of two Phase III clinical trials of tabalumab.
The Lupus Foundation of America announced four grants that will allow lupus investigators to continue critical lupus research. Another grant will be used to develop a groundbreaking diagnostic tool for children with lupus-related kidney inflammation, or lupus nephritis.
Dr. Gary Gilkeson discusses the role of adult stem cells in the immune system and how they can be used to manage lupus.
Study funded by the Foundation's National Lupus Research Program secures NIH planning grant to develop a multi-center trial of mesenchymal stem cells.
Flare rates among participants receiving a low dose of the b-cell blocker did not meet primary endpoint but were lower for individuals receiving a higher dose.
Treat-to-Target is a treatment approach that has been used successfully in other diseases, including rheumatoid arthritis and diabetes. An international group of lupus experts has developed a set of recommendations for using this principle in lupus.
An international group of lupus experts has developed a set of recommendations to implement the treat-to-target strategy for managing lupus.
Lupus in the kidneys, also known as nephritis, can be difficult. Dr. Joan T. Merrill, Lupus Foundation of America's Medical Director, explains the risk for lupus in the kidneys, current treatment options, and hope for the future.
Sandra C. Raymond, President and CEO of Lupus Foundation of America, was featured on BioCentury This Week to speak about lupus and the Accelerating Medicines Partnership (AMP). Watch now!
Study examines the effects of the antimalarial drug, hydroxycloroquine, on antiphospholipid antibodies that are responsible for pregnancy complications in women with lupus and antiphospholipid syndrome.
Results from a small pilot study provide hope that lupus disease activity can be suppressed in children with lupus. Read more.
Lupus Foundation of America supported study finds combination therapy that includes hydroxychloroquine may be beneficial to pregnant patients with lupus and/or antiphospholipid syndrome.
Dr. Gary Gilkeson of the Medical University of South Carolina discusses his Lupus Foundation of America funded study on the potential use of human mesenchymal stem cells as a therapy for lupus.
Dr. Kenneth Kalunian discusses the Lupus Foundation of America Collective Data Analysis Initiative (LFA CDAI) which is providing insight into the impact various background medications may have on lupus clinical trial outcomes.
In her Expert Column, Dr. Joan T. Merrill, Medical Director, explains why antimalarial medicines are now used to treat lupus.
Ask the Expert: Dr. Betsy Blazek O'Neill discusses complementary medicines and lupus
According to research presented this week at the American College of Rheumatology Annual Meeting, researchers have identified three potentially modifiable risk factors and one protective medication that may improve the health of people living with lupus.
Researchers from the University of California and Brigham and Women’s Hospital in Boston recently examined adherence among Medicaid beneficiaries with lupus to prescribed medications and found the patients were not following treatment plans, putting themselves at risk for poor outcomes.
The U.S. Department of Defense (DOD) Medical Research Program announces two new lupus research grant awards, bringing the total DoD funds to date for support of lupus research to $14 million.
The Health Insurance Marketplace offers coverage to many Americans who currently do not have health insurance. We have gathered relevant links to help you locate the information you need to know.
Cell based therapies are a growing interest in all areas of medicine as they are viewed as long term solutions rather than temporary fixes. A recent journal article highlights progress made in better understanding the potential for two basic types of adult stem cells.
Lupus nephritis, which can damage and scar the kidneys, is one of the most common and serious complications of lupus. This new study suggests that with the right induction regimen, it may be possible to avoid maintenance (long-term) treatment with oral steroids.
Learn what makes lupus so different from many other diseases and why lupus is a cruel mystery.
People with lupus who were treated with hydroxychloroquine (HCQ), an anti-malarial drug, early after a diagnosis of lupus had less cumulative organ damage at three years after diagnosis than those who did not receive HCQ, according to a new analysis.
A new medical education curriculum to help medical professionals make early diagnosis of lupus has been unveiled by representatives of The Lupus Initiative in Washington, DC.
Making gains against lupus kidney disease
Our national lupus research program aggressively seeks to advance the science and medicine of lupus and to improve the quality of life for all people affected by lupus.
In addition to medications and other medical care from doctors, a large and growing number of people turn to other healing practices to try to improve their health.
Rontalizumab is a potential new drug to treat lupus. It reduces the effects of the excessive interferon-alpha that is so characteristic of lupus. The researchers hoped to learn about the safety and tolerability of rontalizumab in people with mild lupus disease activity.
People with lupus are at increased risk of cardiovascular disease, especially when taking steroids. The use of anti-malarial drugs, such as hydroxychloroquine, significantly reduces this risk.
This study examined the long-term safety of belimumab over a 4-year period in people with lupus. The results highlight the long-term safety of belimumab over a 4-year period.
The researchers hoped to learn about possible differences in treatment preferences for lupus among members of different racial/ethnic patient groups, as well as demographic or clinical characteristics associated with such preferences.
Dr. Richard Furie of the North Shore-Long Island Jewish Health System provides an overview of how lupus is treated.
Lupus Foundation of America Medical Director Dr. Joan Merrill provides an overview of lupus and its health effects.
The findings highlight specific kinds of changes in lupus biomarkers that are most associated with effective use of belimumab in the treatment of lupus.
Biomarkers are very much in the news today, in stories about how to determine who is at risk for a disease or condition, or the ways in which a group or population is reacting to a particular treatment. They also play a role in the development of new medications.
The results of this study reveal differences in autoantibody profiles over time in people with lupus, with important ethnicity-related differences, and their relationship to lupus-mediated organ damage over time.
As people with lupus have become increasingly educated about their disease and involved in their medical care, input from patients about their condition has become increasingly important and useful. Recently, the Lupus Damage Index Questionnaire (LDIQ) was developed for this purpose and captures the spectrum of knowledge acquired from the SDI in a patient-reported questionnaire.
The New England Journal of Medicine published results from a long-term study for the treatment of lupus nephritis.
Dr. Emily von Scheven of the University of California at San Francisco discusses the development of consensus treatment plans for proliferative nephritis in juvenile systemic lupus.
Dr. Michelle Petri of the Johns Hopkins University Medical Center discussed the results of a study of vitamin D supplementation in people with lupus.
Lupus Foundation of America Funded Research First to Use Pooled Data from Previous Treatment Trials.
The Rhuematologist features "The Lupus Initiative," a national health care provider education initiative to improve lupus diagnosis, treatment, and management among minorities.
National lupus organizations, and individuals with lupus and their families around the world, are rallying to protect access to new treatments of lupus.
The researchers hoped to learn about the safety and efficacy of two influenza A (H1N1) vaccinations given to people with lupus.
The researchers aimed to determine the effects of the ISN-RPS re-classifications for lupus nephritis on patient outcomes.
A meeting of key stakeholders from the federal government, industry, and academia will be discussing pediatric rheumatic drug treatments and a consolidated adverse events registry.
Dario Dieguez, PhD, from the Lupus Foundation of America joined leading NIH lupus experts to explore current issues in lupus, including risk factors and treatment therapies.
Program provides lupus education to nurses, pharmacists, and pharmacy technicians.
Since lupus nephritis can be severe and the therapy can be toxic, it is important to be able to predict which patients would most benefit from long-term treatment.
The U.S. Food and Drug Administration (FDA) approved the drug, BENLYSTA®, for the treatment of lupus, an autoimmune disease.
There are a number of treatments used for lupus nephritis, but none of them are approved by the U.S. Food and Drug Administration (FDA). The researchers hoped to compare the efficacy and safety of MMF and azathioprine as maintenance therapy.
Keeping track of your medications, and taking them correctly, can feel overwhelming. Learn more about how to get the most out of your medications.
You know the importance of following your doctor’s guidelines about medication, exercise, and rest; reducing stress; and eating a healthy diet. But if you’re like many people with lupus, at one time or another you’ve come across a dietary or herbal supplement that really sounds as though it could help you. So, what do you do?
LFA-Funded Research Improves the Outlook for Childhood Lupus
Dr. Isenberg discusses several of the new agents under evaluation for lupus and looks to ways lupus treatment will change with evolving technology and new scientific findings.
Hydroxychloroquine belongs to the family of medicines called “antimalarials” (AMs), which are also classified as disease-modifying anti-rheumatic drugs, or DMARDs. These drugs were initially used to prevent and to treat malaria but are no longer used for those purposes.
Dr. David Wofsy of the University of California, San Francisco, leads a discussion and takes questions about being newly diagnosed and living with lupus.
The researchers hoped to learn whether cognitive behavioral thearpy could help people with lupus cope with stress, anxiety, and depression, all of which may co-occur with a chronic illness.
This trial was the first stage of testing for rontalizumab, which is a new treatment that interferes with an inflammatory protein called "interferon-alpha."
An introduction to lupus and the services of the Lupus Foundation of America.
Join us at Marlins Park for 2016 Walk to End Lupus Now! Come and spend your afternoon at the ballpark while helping us raise awareness!
The Living Well With Lupus Symposium provides information and strategies to help you live well with lupus.
Lupus Medical Symposium, "Finding the U in LUPUS: Simple Strategies for Living with Lupus without Losing Yourself" presented by Hilary Pick, LPC and addressing eye concerns with "The Aging Eye" presented by Bhavna Sheth, MD, MBA
This educational teleconference will address complications, medical evaluation and treatment as it relates to kidney involvement in lupus.
Don't miss this opportunity to learn from some of the world's leading lupus experts from the comfort and privacy of your home!
Please join us for our Living Well with Lupus Seminar in Orlando.
Thank you Palm Beach for coming out to Walk to End Lupus Now. You have until July 5 to turn in your donations and help us reach our goal.
Thank you Orlando for coming out to Walk to End Lupus Now. You have until June 21 to turn in your donations and help us reach our goal.
Thank you Jacksonville for coming out to Walk to End Lupus Now. You have until April 13 to turn in your donations and help us reach our goal.
Are you interested in starting a group in your area or becoming a co-facilitator of an exisiting group? If, so we invite you to attend our next facilitator training.
Thank you for Melbourne for coming out to Walk to End Lupus Now. You have until December 14 to turn in your donations and help us reach our goal.
Thank you for Miami for coming out to Walk to End Lupus Now. You have until November 30 to turn in your donations and help us reach our goal.
Join us for our third annual Southwest Florida Walk to end Lupus now in Naples. Lets rally together to create awareness of lupus while raising funds to fight this terrible disease.
We are heading back to the Palm Beach Zoo for our South Florida Spring Walk to End Lupus Now! Please join us as we rally together to create awareness of lupus while raising funds to fight this terrible disease.
NEW in 2015! The Walk to End Lupus Now is coming to Northern Florida in Jacksonville. Join us as we rally together to create awareness of lupus while raising funds to fight this terrible disease.
What you need to know to help with issues surrounding disability.
Join us for the SLE Self Help Leader Training - a two day training course designed to prepare people to teach others with lupus how to take a more active part in their health care and live better despite lupus.
Join us at Wickham Park for a fun afternoon while raising funds and awareness for those suffering from the cruel mystery of lupus.
Join us to learn about current treatments methods and new options that are up and coming.
Learn more about scientific research regarding specific types of complementary and alternative medicine in this session.
This educational workshop will address management of severe and chronic pain associated with lupus including practical tips and precautions, prevention, and coping strategies to help manage pain.
Register Today for the Annual Lupus Education Conference in St. Louis
This seminar will provide information on 2 different topics: Lupus and the Musculoskeletal System and Complementary and Alternative Medicine.
Feel empowered to advocate for yourself on a social and political level to overcome healthcare barriers.
Participants will learn ways to manage severe and chronic pain including medications, therapies, and coping strategies.
Participants will learn ways to manage severe and chronic pain including medications, therapies, and coping strategies.
Learn how to help manage severe and chronic pain associated with lupus including practical tips and precautions, prevention, and coping strategies.
Learn about complementary therapies and lifestyle changes one can incorporate into their daily routine to enhance health and maximize lupus control.
Lupus: Ask the Experts is a series of live educational teleconferences designed to provide you with important information about living with lupus.